TFS Chemicals - Aspire
Pharma Focus America
Sino Biological - Cytokine

Ubiquigent and Debiopharm Collaborate on USP1 Inhibitor Program for Debio 0432

Wednesday, March 27, 2024

Ubiquigent Limited, a company focused on drug discovery and development through innovative DUB modulators, has announced a collaboration with Debiopharm, a biopharmaceutical firm specializing in treatments for cancer and infectious diseases. This partnership aims to support the development of Debiopharm's Debio 0432, a USP1 inhibitor program.

In this agreement, Ubiquigent will utilize its specialized DUB platform and expertise to create novel target engagement assays essential for Debio 0432's progression towards clinical trials. Debio 0432, currently in late-stage preclinical development, shows promise as a small molecule therapy targeting USP1, a key player in the DNA damage repair pathway. By inhibiting USP1, Debio 0432 could potentially induce synthetic lethality in tumors with DNA repair gene deficiencies.

Jason Mundin, CEO of Ubiquigent, expressed excitement about the collaboration, highlighting the company's successful partnerships with clinical stage entities and its comprehensive platform covering various aspects of drug discovery and development.

Bertrand Ducrey, CEO of Debiopharm, emphasized the importance of Ubiquigent's specialized drug discovery platform in supporting the progression of the USP1 inhibitor program towards clinical trials. Targeting USP1 to disrupt DNA damage repair represents a promising approach in cancer treatment.

Overall, the collaboration between Ubiquigent and Debiopharm signifies a joint effort to advance novel therapeutics targeting the DUB pathway for addressing significant medical needs in cancer treatment.



patheon - Mastering API production at every scaleWorld Vaccine Congress Europe 2024World Orphan Drug Congress 2024Future Labs Live USA 2024patheon - Revolutionizing PharmaHealthcare CNO SummitHealthcare CMO Summit